Can Find Under Yahoo News Finance or Copy and paste Title of Article to Google.
Article Name :Analyst says overreaction to Ariad warning label
Analyst says market overreacted to warning label on new Ariad Pharma leukemia drug Iclusig
Associated Press 12/17/12
THE ANALYSIS: William Blair's Y. Katherine Xu said in a client note that the market's reaction to the warning label was excessive and has opened up a buying opportunity for investors.
She also believes that the warning label likely won't deter the initial target patients from taking the drug, as they will have failed all other therapies and do not have any other options.
The analyst reaffirmed an "Outperform" rating and $28 price target on the Cambridge, Mass., company.